Detailed narrative
Q2 & H1 FY25 Financial Performance Overview
Orchid Pharma reported Q2 FY25 sales of INR222.7 crores and EBITDA of INR37.5 crores. For the first half of FY25, sales totaled INR467.1 crores, reflecting a robust 22% increase over H1 FY24. EBITDA for H1 FY25 significantly improved to INR78.6 crores from INR54.7 crores in H1 FY24, representing approximately 43.7% YoY growth. The operating EBITDA also saw a 39% increase to INR66.8 crores, demonstrating continued focus on cost control and efficiency.
ORBLICEF India Launch and Initial Market Traction
ORBLICEF, the company's drug product for Enmetazobactam-Cefepime, was successfully launched in the Indian market during the last week of September. Management expressed optimism about its impact, citing promising initial microbiological results on Indian strains. A marketing partnership with Cipla is expected to drive sales momentum, ensuring pan-India availability. Initial doctor responses have been encouraging, with the molecule showing effectiveness against existing empirical therapy space of antibiotics.
Enmetazobactam Global Commercialization Update
Sales of Enmetazobactam have officially begun in the EU market, though initial numbers are insignificant as sales recently started. In the U.S., the company is still awaiting news of development, remaining optimistic for forward movement. Management reiterated a long-term estimate of $2 billion to $3 billion in lifetime sales for this product, combining potential from the U.S., Europe, and China markets.
Key Project Updates and Capacity Expansion
Orchid Pharma commissioned its small-capacity enhancement project ahead of schedule, completing validation batches. This project is expected to contribute 15-20% to overall capacity, supporting future growth. The 7ACA project broke ground on Ganesh Chaturthi, with work now expected to proceed swiftly. The total planned capex for the 7ACA plant is about INR700 crores, with INR35 crores already spent, and commissioning targeted for April 2026.
Long-term R&D and Strategic Focus
Beyond current projects, management highlighted ongoing research in Cephalosporins, a space with few competitors, positioning Orchid Pharma as a potential leader. The company aims to develop process development for newer molecules going off-patent. The 7ACA project is expected to provide significant insight into fermentation technology, creating a platform for developing further fermentation-based products, a capability not common among Indian companies.
Regulatory and Operational Updates
The company's core filing for Ceftazidime/Avibactam received observations from the U.S. FDA. Management stated these deficiencies were not serious and expects to refile within the current quarter after generating necessary data. The last FDA inspection was in July 2019, and the company is prepared for the next inspection, though no specific date has been communicated.
Dhanuka Group Performance and Outlook
The Dhanuka Group reported sales of INR275 crores for the first six months. Last year's annual sales were INR550 crores, with management expecting approximately 5% growth for the current fiscal year. The EBITDA margin for the Dhanuka Group is anticipated to remain in the single digits.